45 results about "Ebola virus infection" patented technology

In this application are described Ebola GP monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and / or therapeutical treatment of Ebola virus infections in vitro and in vivo.

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and / or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

The invention relates to an active molecule capable of suppressing gene replication of Ebola virus. The active molecule is compsoed of nanogranule formulation of HKP or SLiC or RPH vector and siRNA cocktail for preventing and treating Ebola virus infection. The active molecule specificly relates to the siRNA molecule cocktain of targeted Ebola virus, cocktail siRNA composition of targeted Ebola virus gene conservative region, nanoparticle of siRNA cocktail and Histidine-lysine copolymer (HKP), or / and spermine-lipid-cholesterol (SLiC)nanoparticle formulation composition; composition of siRNA cocktail and HKP or SLiC nanoparticle formulation. The formulation is modified by Arg-Gly-Asp(RGD) polypeptide ligands which is specific to a endothelial cell surface acceptor or erythrocyte, and is called RGD-PEG-HKP(RPH) vector system. The invention also relates to a method for testing new siRNA formualtion in cell cultrue, a method for testing new siRNA formulation in guinea pig model and monkey model and a method for testing nanoparticle-containing siRNA formualtion in injection liquid for human.

The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of symptoms of a disease selected from the group consisting of: Ebola virus infection, HIV infection, ataxia, environmental enteropathy, cancer, hangover, inflammatory disease, and porcine epidemic diarrhea. In preferred embodiments, the composition includes a combination of one or more amino acids selected from the group comprising lysine, aspartic acid, glycine, isoleucine, threonine, tyrosine, valine, tryptophan, asparagine and / or serine.

The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of symptoms of a disease selected from the group consisting of: Ebola virus infection, HIV infection, ataxia, environmental enteropathy, cancer, hangover, inflammatory disease, and porcine epidemic diarrhea. In preferred embodiments, the composition includes a combination of one or more amino acids selected from the group comprising lysine, aspartic acid, glycine, isoleucine, threonine, tyrosine, valine, tryptophan, asparagine and / or serine.

The invention discloses application of azithromycin and telithromycin in anti-ebola-virus infection, including application of azithromycin or / and telithromycin in prevention or treatment of ebola virus infection or combined application of azithromycin or / and telithromycin with other anti-virus drugs.

The invention provides a nanometer antibody ebo7c2 for neutralizing Ebola viruses and application of the nanometer antibody to preparing medicines for preventing or treating Ebola virus infection. Amino acid sequences of the nanometer antibody are shown as SEQ ID NO:1, and nucleotide sequences for genes for encoding the nanometer antibody ebo7c2 are shown as SEQ ID NO:2. The nanometer antibody and the application have the advantages that CH2 structural domains m01s of human antibodies IgG1 are used as skeletons of the nanometer antibody, and amino acid of the nanometer antibody is different from amino acid sequences of the CH2 structural domains m01s in three loop zones; the nanometer antibody ebo7c2 can be bound with envelope proteins of the Ebola viruses; the nanometer antibody ebo7c2 has small molecular weights and is excellent in tissue permeability and ability of being bound with antigen epitopes with steric hindrance effects; the nanometer antibody is provided with the m01s skeletons and can be bound with FcRn, and the plasma half-life of the nanometer antibody can possibly reach 10 hours; the nanometer antibody ebo7c2 can be expressed in prokaryotic expression systems and is low in production cost and short in cycle.

The present invention is directed to methods for treating ebola virus infections or Marburg virus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.